Patient-level Meta-Analysis Confirms Benefits of Toujeo® Regardless of Age of Onset of Type 2 Diabetes

– Starting with or switching to Toujeo® provided comparable glycemic control with less hypoglycemia vs Lantus® in all sub-groups   –

What: 

Results from a new meta-analysis of patient-level 6-month data from the EDITION 1, 2 and 3 Phase 3 clinical trials demonstrate that in adults with type 2 diabetes, the benefits of Toujeo® (insulin glargine [rDNA origin] injection, 300 Units/mL) are not related to age at onset of diabetes. When stratified by age at onset of diabetes, the analysis shows comparable glycemic control with reduced* risk of hypoglycemic (low blood sugar) events at night and at any time of day (24 hr) in each sub-group with Toujeo® compared with Lantus® (insulin glargine [rDNA origin] injection, 100 Units/mL).

The study abstract is titled: Age of diabetes onset: Glycemic control and hypoglycemia benefit with new insulin glargine 300 U/mL in T2DM (Twigg S et al. Poster presentation 0357-PD, December 1, 2015).

* Risk reduction is statistically significant for all patient sub-groups, except for any-time (24 hr) hypoglycemic events in patients aged >50 at onset of diabetes, where the risk reduction with Toujeo is numerical. 

Who: 

The lead author of this poster presentation is Prof. Stephen Twigg, Kellion Professor of Endocrinology, Sydney Medical School, Australia. 

When: 

Tuesday, December 1, 2015 (Poster presented all day; discussion 13:00–14:00) 

Where: 

International Diabetes Federation 23rd World Diabetes Congress, Vancouver Convention Centre (VCC), Vancouver, Canada. Poster displayed in poster area; Discussion at Poster Terminal 1.  

Contact: 

To request an interview to discuss this and other Sanofi Diabetes-sponsored research with Riccardo Perfetti, Senior Medical Officer, Vice President Medical Affairs, please contact Philip McNamara, Global Diabetes Communications (Tel.: +1 908 981 5497; philip.mcnamara@sanofi.com)